Bristol-Myers Squibb Company PFD CONV 2
BMYMP · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $12,222,000 | $12,269,000 | $11,201,000 | $12,342,000 |
| % Growth | -0.4% | 9.5% | -9.2% | – |
| Cost of Goods Sold | $3,435,000 | $4,199,000 | $3,861,000 | $4,918,000 |
| Gross Profit | $8,787,000 | $8,070,000 | $7,340,000 | $7,424,000 |
| % Margin | 71.9% | 65.8% | 65.5% | 60.2% |
| R&D Expenses | $2,528,000 | $2,262,000 | $2,236,000 | $2,788,000 |
| G&A Expenses | $0 | $0 | $0 | $352,000 |
| SG&A Expenses | $1,789,000 | $1,691,000 | $1,583,000 | $1,852,000 |
| Sales & Mktg Exp. | $0 | $0 | $1,584,000 | $1,500,000 |
| Other Operating Expenses | $831,000 | $0 | $0 | $253,000 |
| Operating Expenses | $5,148,000 | $3,953,000 | $3,819,000 | $4,893,000 |
| Operating Income | $3,639,000 | $4,117,000 | $3,521,000 | $2,531,000 |
| % Margin | 29.8% | 33.6% | 31.4% | 20.5% |
| Other Income/Exp. Net | -$525,000 | -$2,344,000 | -$550,000 | -$2,356,000 |
| Pre-Tax Income | $3,114,000 | $1,773,000 | $2,971,000 | $175,000 |
| Tax Expense | $919,000 | $460,000 | $509,000 | $99,000 |
| Net Income | $2,201,000 | $1,310,000 | $2,456,000 | $72,000 |
| % Margin | 18% | 10.7% | 21.9% | 0.6% |
| EPS | 1.08 | 0.64 | 1.21 | 0.036 |
| % Growth | 68.8% | -47.1% | 3,308.5% | – |
| EPS Diluted | 1.08 | 0.64 | 1.2 | 0.035 |
| Weighted Avg Shares Out | 2,037,963 | 2,035,000 | 2,031,000 | 2,029,026 |
| Weighted Avg Shares Out Dil | 2,037,963 | 2,038,000 | 2,037,000 | 2,037,000 |
| Supplemental Information | – | – | – | – |
| Interest Income | $161,000 | $139,000 | $0 | $0 |
| Interest Expense | $480,000 | $485,000 | $494,000 | $496,000 |
| Depreciation & Amortization | $993,000 | $1,029,000 | $1,012,000 | $1,880,000 |
| EBITDA | $4,587,000 | $3,287,000 | $4,477,000 | $2,551,000 |
| % Margin | 37.5% | 26.8% | 40% | 20.7% |